Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Sexually Transmitted Diseases

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 43 articles:
HTML format
Text format



Single Articles


    January 2018
  1. RAZZAGHI H, Saraiya M, Thompson TD, Henley SJ, et al
    Five-year relative survival for human papillomavirus-associated cancer sites.
    Cancer. 2018;124:203-211.
    PubMed     Text format     Abstract available


    December 2017
  2. PRINTZ C
    Women who undergo HPV testing receive earlier detection and treatment of cervical precancers.
    Cancer. 2017;123:4751.
    PubMed     Text format    


  3. DAHLSTROM KR, Anderson KS, Field MS, Chowell D, et al
    Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer.
    Cancer. 2017;123:4886-4894.
    PubMed     Text format     Abstract available


    November 2017
  4. LANG KUHS KA, Kreimer AR, Trivedi S, Holzinger D, et al
    Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
    Cancer. 2017;123:4382-4390.
    PubMed     Text format     Abstract available


    October 2017
  5. GLEBER-NETTO FO, Zhao M, Trivedi S, Wang J, et al
    Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31063.
    PubMed     Text format     Abstract available


  6. NELSON RA, Lai LL
    Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer.
    Cancer. 2017;123:4013-4021.
    PubMed     Text format     Abstract available


    September 2017
  7. DESHMUKH AA, Chiao EY, Cantor SB, Stier EA, et al
    Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness.
    Cancer. 2017 Sep 26. doi: 10.1002/cncr.31035.
    PubMed     Text format     Abstract available


  8. TAO X, Austin RM, Zhang H, Zhang L, et al
    Histopathologic follow-up and HPV test results with HSIL Papanicolaou test results in China's largest academic women's hospital.
    Cancer. 2017 Sep 8. doi: 10.1002/cncy.21914.
    PubMed     Text format     Abstract available


  9. PRINJA S, Bahuguna P, Faujdar DS, Jyani G, et al
    Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
    Cancer. 2017;123:3253-3260.
    PubMed     Text format     Abstract available


    August 2017
  10. TRACHT JM, Davis AD, Fasciano DN, Eltoum IA, et al
    Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?
    Cancer. 2017 Aug 17. doi: 10.1002/cncy.21905.
    PubMed     Text format     Abstract available


    July 2017
  11. AN Y, Park HS, Kelly JR, Stahl JM, et al
    The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Cancer. 2017;123:2762-2772.
    PubMed     Text format     Abstract available


  12. CHANDRASEKHARAPPA SC, Chinn SB, Donovan FX, Chowdhury NI, et al
    Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30802.
    PubMed     Text format     Abstract available


    June 2017
  13. GE Y, Christensen P, Luna E, Armylagos D, et al
    Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
    Cancer. 2017 Jun 2. doi: 10.1002/cncy.21875.
    PubMed     Text format     Abstract available


    May 2017
  14. MALM IJ, Fan CJ, Yin LX, Li DX, et al
    Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma.
    Cancer. 2017;123:1768-1777.
    PubMed     Text format     Abstract available


  15. GUO M, Khanna A, Wang J, Dawlett MA, et al
    Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Cancer. 2017 May 12. doi: 10.1002/cncy.21877.
    PubMed     Text format     Abstract available


  16. SMALL W JR, Bacon MA, Bajaj A, Chuang LT, et al
    Cervical cancer: A global health crisis.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30667.
    PubMed     Text format     Abstract available


  17. PRINTZ C
    CDC recommends only 2 HPV doses for younger adolescents.
    Cancer. 2017;123:1485.
    PubMed     Text format    


  18. FAKHRY C, Westra WH, Wang SJ, van Zante A, et al
    The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.
    Cancer. 2017;123:1566-1575.
    PubMed     Text format     Abstract available


    April 2017
  19. ZUMSTEG ZS, Lok BH, Ho AS, Drill E, et al
    The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Cancer. 2017;123:1345-1353.
    PubMed     Text format     Abstract available


  20. ALSBEIH GA, Al-Harbi NM, Bin Judia SS, Khoja HA, et al
    Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.
    Cancer. 2017 Apr 10. doi: 10.1002/cncr.30635.
    PubMed     Text format     Abstract available


  21. D'SOUZA G, Robbins HA
    Sexual and relationship health among survivors of oropharyngeal or oral cavity squamous cell carcinoma.
    Cancer. 2017;123:1092-1094.
    PubMed     Text format    


    March 2017
  22. BERMAN TA, Schiller JT
    Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30588.
    PubMed     Text format     Abstract available


  23. HAJEK M, Sewell A, Kaech S, Burtness B, et al
    TRAF3/CYLD mutations identify a distinct subset of human papilloma virus-associated head and neck squamous cell carcinoma.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30570.
    PubMed     Text format     Abstract available


  24. BENEVOLO M, Allia E, Gustinucci D, Rollo F, et al
    Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women.
    Cancer. 2017;125:212-220.
    PubMed     Text format     Abstract available


    February 2017
  25. BEADLE BM
    The impact of HPV testing for oropharyngeal cancers: Why the addendum matters.
    Cancer. 2017 Feb 27. doi: 10.1002/cncy.21842.
    PubMed     Text format    


  26. TABERNA M, Inglehart RC, Pickard RK, Fakhry C, et al
    Significant changes in sexual behavior after a diagnosis of human papillomavirus-positive and human papillomavirus-negative oral cancer.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30564.
    PubMed     Text format     Abstract available


    January 2017
  27. SHER DJ, Rusthoven CG, Khan SA, Fidler MJ, et al
    National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma.
    Cancer. 2017;123:273-282.
    PubMed     Text format     Abstract available


    December 2016
  28. OVESTAD IT, Dalen I, Hansen E, Loge JL, et al
    Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Cancer. 2016 Dec 5. doi: 10.1002/cncy.21807.
    PubMed     Text format     Abstract available


  29. BAUMAN JE, Cohen E, Ferris RL, Adelstein DJ, et al
    Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30449.
    PubMed     Text format     Abstract available


    November 2016
  30. DE BROT L, Pellegrini B, Moretti ST, Carraro DM, et al
    Infections with multiple high-risk HPV types are associated with high-grade and persistent low-grade intraepithelial lesions of the cervix.
    Cancer. 2016 Nov 21. doi: 10.1002/cncy.21789.
    PubMed     Text format     Abstract available


    October 2016
  31. PATADJI S, Li Z, Pradhan D, Zhao C, et al
    Significance of high-risk HPV detection in women with atypical glandular cells on Pap testing: Analysis of 1857 cases from an academic institution.
    Cancer. 2016 Oct 24. doi: 10.1002/cncy.21791.
    PubMed     Text format     Abstract available


  32. DOXTADER EE, Brainard JA, Underwood D, Chute DJ, et al
    Knowledge of the HPV status biases cytotechnologists' interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy.
    Cancer. 2016 Oct 12. doi: 10.1002/cncy.21783.
    PubMed     Text format     Abstract available


    September 2016
  33. SILVER MI, Schiffman M, Fetterman B, Poitras NE, et al
    The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30277.
    PubMed     Text format     Abstract available


    August 2016
  34. MAZUL AL, Taylor JM, Divaris K, Weissler MC, et al
    Oral health and human papillomavirus-associated head and neck squamous cell carcinoma.
    Cancer. 2016 Aug 29. doi: 10.1002/cncr.30312.
    PubMed     Text format     Abstract available


  35. JIMENO A, Machiels JP, Wirth L, Specenier P, et al
    Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Cancer. 2016 Aug 15. doi: 10.1002/cncr.30256.
    PubMed     Text format     Abstract available


    July 2016
  36. BURGER EA, Lee K, Saraiya M, Thompson TD, et al
    Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines.
    Cancer. 2016;122:2057-66.
    PubMed     Text format     Abstract available


  37. HORNE ZD, Glaser SM, Vargo JA, Ferris RL, et al
    Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas.
    Cancer. 2016;122:2021-30.
    PubMed     Text format     Abstract available


    June 2016
  38. GARDEN AS, Fuller CD, Rosenthal DI, William WN Jr, et al
    Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer.
    Cancer. 2016;122:1702-7.
    PubMed     Text format     Abstract available


    May 2016
  39. BISHOP JA, Ha PK
    Human papillomavirus detection in a "Digital" age.
    Cancer. 2016;122:1502-4.
    PubMed     Text format    


  40. BIRON VL, Kostiuk M, Isaac A, Puttagunta L, et al
    Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction.
    Cancer. 2016;122:1544-51.
    PubMed     Text format     Abstract available


  41. CRACCHIOLO JR, Baxi SS, Morris LG, Ganly I, et al
    Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base.
    Cancer. 2016;122:1523-32.
    PubMed     Text format     Abstract available


  42. PATEL MA, Blackford AL, Rettig EM, Richmon JD, et al
    Rising population of survivors of oral squamous cell cancer in the United States.
    Cancer. 2016;122:1380-7.
    PubMed     Text format     Abstract available


  43. REUSCHENBACH M, Pauligk C, Karbach J, Rafiyan MR, et al
    A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
    Cancer. 2016;122:1425-33.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: